The Clinical Sample Acquisition and Repository Scientific Research Support Component (SRSC) will provide human clinical samples required for the studies outlined in the CHAVI-ID research plan. One key goal of CHAVI-ID is to study subjects that make broad neutralizing antibodies (BnAbs) in order to understand how best to induce BnABs. Another key goal is to receive vaccine trial samples from collaborating networks and to provide these samples to CHAVI-ID investigators. The clinical samples that are needed for the B, T and Innate cell studies as well as studies in the SRSCs, are those from chronically infected subjects who have been extensively characterized for their ability to make broad neutralizing antibodies (BnAbs), and samples from HIV-1 vaccine trials carried out by the HIV Vaccine Trials Network (HVTN), the Military HIV Research Program (MHRP) or the NIH Vaccine Research Center (VRC) as well as control samples. It is also important to have a sample repository comprised of both samples from control groups, samples from volunteers in vaccine trials as well as samples from both acute and chronic HIV-1 infection cohorts, such that when opportunities arise to test new hypotheses that require clinical material, CHAVI-ID research can move quickly ahead without stopping to write and get new clinical protocols approved.
Specific Aims Aim 1. To recruit and maintain the CHAVI-ID clinical sites for CHAVI-ID studies.
Aim 2. To maintain high quality specimen processing laboratories at the CHAVI-ID sites to ensure the highest quality sample acquisition.
Aim 3. To maintain CHAVI-ID repository sample storage facilities for distribution to CHAVI-ID investigators.

Public Health Relevance

Access to HIV-infected patients followed over time is essential to understanding the immunology of HlV-1 infection. Having experienced and skilled clinical research personnel is essential for obtaining and maintaining high quality clinical specimens to support the research that can lead to successful vaccine design.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Chen, Shuobing; Wu, Jiayi; Lu, Ying et al. (2016) Structural basis for dynamic regulation of the human 26S proteasome. Proc Natl Acad Sci U S A 113:12991-12996
Tian, Ming; Cheng, Cheng; Chen, Xuejun et al. (2016) Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166:1471-1484.e18
Love, Tanzy M T; Park, Sung Yong; Giorgi, Elena E et al. (2016) SPMM: estimating infection duration of multivariant HIV-1 infections. Bioinformatics 32:1308-15
Barton, John P; Goonetilleke, Nilu; Butler, Thomas C et al. (2016) Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nat Commun 7:11660
Astronomo, Rena D; Santra, Sampa; Ballweber-Fleming, Lamar et al. (2016) Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine 14:97-111
Herschhorn, Alon; Ma, Xiaochu; Gu, Christopher et al. (2016) Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. MBio 7:
Theiler, James; Yoon, Hyejin; Yusim, Karina et al. (2016) Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Sci Rep 6:33987
Ding, Shilei; Tolbert, William D; Prévost, Jérémie et al. (2016) A Highly Conserved gp120 Inner Domain Residue Modulates Env Conformation and Trimer Stability. J Virol 90:8395-409
Jeffries Jr, T L; Sacha, C R; Pollara, J et al. (2016) The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. Mucosal Immunol 9:414-27
Abdul-Jawad, Sultan; Ondondo, Beatrice; van Hateren, Andy et al. (2016) Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Mol Ther 24:375-84

Showing the most recent 10 out of 160 publications